We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Hospira’s Remicade Biosimilar Shows Comparable Patient Response in EU Study
Hospira’s Remicade Biosimilar Shows Comparable Patient Response in EU Study
Postmarket monitoring results on Hospira’s biosimilar of Janssen’s Remicade continue to show comparable patient response to the reference, the generics maker says.